Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03395080 · ClinicalTrials.gov registry record · Phase 2
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
A Phase 2 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT03395080 is a Phase 2 study that has completed, run by Leap Therapeutics. The registered enrollment target is 111 participants.
The verdict
NCT03395080, a Phase 2 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
Interventions
- DRUG Paclitaxel
- DRUG 300mg DKN-01
- DRUG 600mg DKN-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2021-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03395080
The ClinicalTrials.gov registry entry for NCT03395080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leap Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT03395080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03395080 about?
NCT03395080 is a clinical study titled "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma". A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
What is the current status of trial NCT03395080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2018-03-05. Estimated completion is 2021-01-27.
What interventions are being tested in trial NCT03395080?
The interventions under investigation include: Paclitaxel (DRUG), 300mg DKN-01 (DRUG), 600mg DKN-01 (DRUG).
Who is sponsoring clinical trial NCT03395080?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.